130 related articles for article (PubMed ID: 33202284)
21. Exceptional Response of
Kerle IA; Scheuble AM; Kobitzsch B; Stocker G; Hiller GGR; Badendick M; William D; Krueger A; Gross T; Koegler A; Hartig A; Richter D; Aust DE; Schroeck E; Heining C; Glimm H; Hacker UT
JCO Precis Oncol; 2024 May; 8():e2400030. PubMed ID: 38820503
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
[TBL] [Abstract][Full Text] [Related]
23. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract][Full Text] [Related]
24. Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Potu H; Peterson LF; Kandarpa M; Pal A; Sun H; Durham A; Harms PW; Hollenhorst PC; Eskiocak U; Talpaz M; Donato NJ
Nat Commun; 2017 Feb; 8():14449. PubMed ID: 28198367
[TBL] [Abstract][Full Text] [Related]
25. Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma.
Kim YJ; Bond GJ; Tsang T; Posimo JM; Busino L; Brady DC
Metallomics; 2019 Aug; 11(8):1430-1440. PubMed ID: 31317143
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic Gq/11 signaling acutely drives and chronically sustains metabolic reprogramming in uveal melanoma.
Onken MD; Noda SE; Kaltenbronn KM; Frankfater C; Makepeace CM; Fettig N; Piggott KD; Custer PL; Ippolito JE; Blumer KJ
J Biol Chem; 2022 Jan; 298(1):101495. PubMed ID: 34919964
[TBL] [Abstract][Full Text] [Related]
27. EHMT2 promotes tumorigenesis in
Li Y; Zhu T; Yang J; Zhang Q; Xu S; Ge S; Jia R; Zhang J; Fan X
Acta Pharm Sin B; 2024 Mar; 14(3):1187-1203. PubMed ID: 38486999
[TBL] [Abstract][Full Text] [Related]
28. INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.
Elbatsh AMO; Amin-Mansour A; Haberkorn A; Textor C; Ebel N; Renard E; Koch LM; Groenveld FC; Piquet M; Naumann U; Ruddy DA; Romanet V; Martínez Gómez JM; Shirley MD; Wipfli P; Schnell C; Wartmann M; Rausch M; Jager MJ; Levesque MP; Maira SM; Manchado E
Nat Cancer; 2024 Mar; 5(3):481-499. PubMed ID: 38233483
[TBL] [Abstract][Full Text] [Related]
29. Uveal melanoma cell lines Mel270 and 92.1 exhibit a mesenchymal phenotype and sensitivity to the cytostatic effects of transforming growth factor beta in vitro.
Doudnikoff C; Leclerc D; Angenard G; Gilot D; Coulouarn C; Mouriaux F
Mol Vis; 2024; 30():160-166. PubMed ID: 38601020
[TBL] [Abstract][Full Text] [Related]
30. Treatment of congenital Langerhans cell histiocytosis with cobimetinib.
Benjelloun G; Roquet-Gravy C; Marot L; Secco LP; Roquet-Gravy PP; Baeck M; Bulinckx A
Pediatr Dermatol; 2024; 41(3):515-517. PubMed ID: 38387093
[TBL] [Abstract][Full Text] [Related]
31. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells.
Vertuani S; Dubrovska E; Levitsky V; Jager MJ; Kiessling R; Levitskaya J
Cancer Immunol Immunother; 2007 Feb; 56(2):193-204. PubMed ID: 16752155
[TBL] [Abstract][Full Text] [Related]
32. Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
Louveau B; Reger De Moura C; Jouenne F; Sadoux A; Allayous C; Da Meda L; Bernard-Cacciarella M; Baroudjian B; Lebbé C; Mourah S; Dumaz N
Melanoma Res; 2024 Apr; 34(2):186-192. PubMed ID: 38141200
[TBL] [Abstract][Full Text] [Related]
33. Development of Vitiligo in Patients Treated With BRAF/MEK Inhibitors: A Systematic Review.
Liu N; Tarafdar N; Georgakopoulos JR; Maliyar K; Sachdeva M; Lytvyn Y; Mufti A; Yeung J
J Cutan Med Surg; 2024; 28(2):200-201. PubMed ID: 38323558
[No Abstract] [Full Text] [Related]
34. GNAQ-mutated primary subcutaneous blue melanoma arising in naevus of Ota presenting as a skin-coloured forehead mass.
Santiago S; Roy SF; Tran TT; Bosenberg M; Weston GK
Pathology; 2024 Apr; 56(3):426-428. PubMed ID: 37872018
[No Abstract] [Full Text] [Related]
35. Development of an Undergraduate Cell Biology Laboratory to Assess Pigmentation and Cell Size in a Zebrafish Model of Uveal Melanoma.
Henle AM
Zebrafish; 2024 Apr; 21(2):137-143. PubMed ID: 38621208
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy.
Booth AEC; Hopkins AM; Rowland A; Kichenadasse G; Smith JR; Sorich MJ
Ther Adv Med Oncol; 2020; 12():1758835920944359. PubMed ID: 32821295
[TBL] [Abstract][Full Text] [Related]
37. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma.
Shoushtari AN; Khan S; Komatsubara K; Feun L; Acquavella N; Singh-Kandah S; Negri T; Nesson A; Abbate K; Cremers S; Musi E; Ambrosini G; Lee S; Schwartz GK; Carvajal RD
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771668
[TBL] [Abstract][Full Text] [Related]
38. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
39. Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance.
Channathodiyil P; May K; Segonds-Pichon A; Smith PD; Cook SJ; Houseley J
NAR Cancer; 2022 Dec; 4(4):zcac032. PubMed ID: 36267209
[TBL] [Abstract][Full Text] [Related]
40. Towards precision medicine in vascular anomalies: Could protein kinase C inhibitors be repurposed for GNAQ/11-related phakomatoses?
Gu Y; Pham JP; Sebaratnam DF
Skin Res Technol; 2024 Jun; 30(6):e13736. PubMed ID: 38837501
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
